Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses
Open Access
- 31 December 2019
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 10 (68) , 7220-7237
Abstract
Oncotarget | https://doi.org/10.18632/oncotarget.27322 Weng In Leong, Rachel Y. Ames, Jessica M. Haverkamp, Laura Torres, Janine Kline, Ashil Bans, Lauren Rocha, Marilena Gallotta, Cristiana Guiducci, Robert L....Keywords
This publication has 50 references indexed in Scilit:
- Coordinated regulation of myeloid cells by tumoursNature Reviews Immunology, 2012
- Cyclophosphamide Induces Dynamic Alterations in the Host Microenvironments Resulting in a Flt3 Ligand-Dependent Expansion of Dendritic CellsThe Journal of Immunology, 2010
- Administration of Cyclophosphamide Changes the Immune Profile of Tumor-bearing MiceJournal of Immunotherapy, 2010
- Mechanisms of Foxp3+ T Regulatory Cell-Mediated SuppressionImmunity, 2009
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activationJournal of Experimental Medicine, 2006
- Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamideBlood, 2005
- Superior Activity of the Type C Class of ISS In Vitro and In Vivo Across Multiple SpeciesDNA and Cell Biology, 2005
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsAnnals of Oncology, 2002